Compare ProShares Ultra Gold ETF (UGL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Gold ETF vs GeneDx Holdings Corp — how do they compare? ProShares Ultra Gold ETF trades at $46.48 (market cap $716.59M), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 2.8× ProShares Ultra Gold ETF's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra Gold ETF for 23 Days and GeneDx Holdings Corp for 19 Days on average.
| UGL | WGS | |
|---|---|---|
Market Cap | $716.59M | $2.02B |
Volume | 2,592,878 | 734,640 |
Sector | Leveraged / Inverse | Health |
52-Week High | $85.62 | $167.51 |
52-Week Low | $42.79 | $34.51 |
Typical Hold Time | 23 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UGL trades at $46.47, up 4.59% in the past 24 hours, but technical indicators signal a bearish trend with moving averages and ADX pointing to selling pressure. Key support lies at $44, while resistance is near $46. The stock lacks disclosed financial ratios, limiting fundamental visibility. Recent news highlights gold price volatility driven by Treasury yields and Federal Reserve policy expectations, influencing sentiment around gold-related equities.
The outlook remains cautious due to weak technical momentum and macroeconomic headwinds from rising rates. Investment opportunity hinges on gold price stabilization, but risks include persistent bearish indicators and sensitivity to interest rate changes. Investors should await clearer fundamental data and technical confirmation of a trend reversal before considering entry.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
